3,4-二氨基吡啶
外观
![]() | |
![]() | |
临床资料 | |
---|---|
商品名 | Firdapse, Ruzurgi |
其他名称 | pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP |
AHFS/Drugs.com | Monograph Monograph |
核准状况 |
|
怀孕分级 | |
给药途径 | By mouth |
ATC码 | |
法律规范状态 | |
法律规范 |
|
药物动力学数据 | |
生物利用度 | 93–100%[5] |
药物代谢 | Acetylation to 3-N-acetylamifampridine |
生物半衰期 | 2.5 hrs (amifampridine) 4 hrs (3-N-acetylamifampridine) |
排泄途径 | Kidney (19% unmetabolized, 74–81% 3-N-acetylamifampridine |
识别信息 | |
| |
CAS号 | 54-96-6 ![]() 446254-47-3 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL |
|
PDB配体ID | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.201 |
化学信息 | |
化学式 | C5H7N3 |
摩尔质量 | 109.13 g·mol−1 |
3D模型(JSmol) | |
熔点 | 218至220 °C(424至428 °F) decomposes |
水溶性 | 24 mg/mL (20 °C) |
| |
|
3,4-二氨基吡啶(英语:3,4-diaminopyridine,缩写3,4-DAP,或简称为二氨吡啶,Amifampridine)是一种有机化合物,分子式C5H7N3,常温常压下为浅黄色或者浅棕色晶体,用于治疗蓝伯-伊顿肌无力症候群(LEMS)[5]。
参考文献
[编辑]- ^ 1.0 1.1 Ruzurgi. Therapeutic Goods Administration (TGA). 24 September 2021 [30 September 2021]. (原始内容存档于2021-09-30).
- ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. (原始内容存档于2022-04-03).
- ^ Summary Basis of Decision (SBD) for Firdapse. Health Canada. 23 October 2014 [29 May 2022]. (原始内容存档于2022-11-04).
- ^ Summary Basis of Decision (SBD) for Ruzurgi. Health Canada. 23 October 2014 [29 May 2022]. (原始内容存档于2022-11-02).
- ^ 5.0 5.1 Firdapse Summary of Product Characteristics (PDF). EMA. February 11, 2010 [2022-11-04]. (原始内容存档 (PDF)于2018-06-20). See EMA Index page, product tab (页面存档备份,存于互联网档案馆)
外部链接
[编辑]- Amifampridine. Drug Information Portal. U.S. National Library of Medicine. [2022-11-04]. (原始内容存档于2022-11-04).
- Amifampridine phosphate. Drug Information Portal. U.S. National Library of Medicine. [2022-11-04]. (原始内容存档于2020-12-12).
|
|